Monte Rosa Therapeutics, Inc. Liability, Defined Benefit Plan
Monte Rosa Therapeutics, Inc. (GLUE) had Liability, Defined Benefit Plan of $5.26 million as of 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Balance Sheet › Liabilities › Liability, Defined Benefit Plan
us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent · last filed 2026-03-17
- 2025-12-31: Liability, Defined Benefit Plan $5.26M.
- 2024-12-31: Liability, Defined Benefit Plan $3.70M.
- 2023-12-31: Liability, Defined Benefit Plan $2.71M.
- 2022-12-31: Liability, Defined Benefit Plan $1.53M.
| Period end | Liability, Defined Benefit Plan |
|---|---|
| 2025-12-31 | $5.26M 10-K · filed 2026-03-17 |
| 2024-12-31 | $3.70M 10-K · filed 2026-03-17 |
| 2023-12-31 | $2.71M 10-K · filed 2025-03-20 |
| 2022-12-31 | $1.53M 10-K · filed 2024-03-14 |
| 2021-12-31 | $2.18M 10-K · filed 2023-03-16 |
| 2020-12-31 | $1.07M 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |